Filtered By:
Specialty: Cardiology
Drug: Nitroglycerin
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 20 results found since Jan 2013.
Haemodynamic effects of the nitroxyl donor cimlanod (BMS ‐986231) in chronic heart failure: a randomized trial
ConclusionIn patients with chronic HFrEF, the haemodynamic effects of cimlanod and NTG are similar. The effects of cimlanod may be explained by venodilatation and preload reduction without additional inotropic or lusitropic effects. Ongoing trials of cimlanod will further define its potential role in the treatment of heart failure.
Source: European Journal of Heart Failure - March 9, 2021 Category: Cardiology Authors: Ninian N. Lang,
Faheem A. Ahmad,
John G. Cleland,
Christopher M. O'Connor,
John R. Teerlink,
Adriaan A. Voors,
Jorg Taubel,
Anke R. Hodes,
Mohamed Anwar,
Ravi Karra,
Yasushi Sakata,
Shiro Ishihara,
Roxy Senior,
Abhishek Khemka,
Narayana G. P Tags: Research Article Source Type: research
Which Hemodynamic Parameter Predicts Nitroglycerin‐Potentiated Head‐Up Tilt Test Response?
ConclusionsOur results show that, 2 minutes after nitroglycerin administration, a statistically significant decrease of SV values (<67 mL) strongly predicts (area under the curve, 0.985; P < 0.0001) the HUTT‐positive response in healthy patients with recurrent unexplained syncope.
Source: Pacing and Clinical Electrophysiology : PACE - February 14, 2015 Category: Cardiology Authors: VINCENZO RUSSO, ANDREA ANTONIO PAPA, CARMINE CIARDIELLO, ANNA RAGO, RICCARDO PROIETTI, PAOLO CALABRÒ, MARIA GIOVANNA RUSSO, GERARDO NIGRO Tags: ORIGINAL ARTICLE Source Type: research
Reduced systemic vascular resistance is the underlying hemodynamic mechanism in nitrate-stimulated vasovagal syncope during head-up tilt-table test
Conclusions Presyncopal symptoms during NTG-stimulated HUTT are SVR mediated, not cardiac output mediated. This study challenges the conventional idea of a decrease in cardiac output mediated by NTG as the overriding cause of presyncopal symptoms during HUTT.
Source: Journal of Arrhythmia - May 3, 2015 Category: Cardiology Source Type: research
A multicenter trial of extracorporeal cardiac shock wave therapy for refractory angina pectoris: report of the highly advanced medical treatment in Japan
In this study, we further addressed the efficacy and safety of CSWT in a single-arm multicenter study approved as a highly advanced medical treatment by the Japanese Ministry of Health, Labour and Welfare. Fifty patients with refractory AP [mean age 70.9 ± 12.6 (SD) years, M/F 38/12] without the indications of percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) were enrolled in 4 institutes in Japan. Ischemic myocardial regions in the left ventricle (LV) were identified by drug-induced stress myocardial perfusion imaging (MPI). Shock waves (200 shots/spot at 0.09 mJ/mm2) were applied t...
Source: Heart and Vessels - June 25, 2018 Category: Cardiology Source Type: research
BP Lowering en Route to Hospital Flops in Acute Stroke
(MedPage Today) -- RIGHT-2 trial shows no benefit, possible harm from nitroglycerin patch
Source: MedPage Today Cardiovascular - February 7, 2019 Category: Cardiology Source Type: news
BP Lowering on Way to Hospital a Fail in Acute Stroke (CME/CE)
(MedPage Today) -- Ambulance-based RIGHT-2 trial shows no benefit from nitroglycerin patch to treat elevated blood pressure
Source: MedPage Today Cardiovascular - February 13, 2019 Category: Cardiology Source Type: news
Hemodynamic Effects of the Nitroxyl Donor Cimlanod (BMS ‐986231) in Chronic Heart Failure: A Randomized Trial
ConclusionIn patients with chronic HFrEF, the hemodynamic effects of cimlanod and NTG are similar. The effects of cimlanod may be explained by venodilatation and preload reduction without additional inotropic or lusitropic effects. Ongoing trials of cimlanod will further define its potential role in the treatment of heart failure.
Source: European Journal of Heart Failure - February 23, 2021 Category: Cardiology Authors: Ninian N. Lang,
Faheem A. Ahmad,
John G. Cleland,
Christopher M. O'Connor,
John R. Teerlink,
Adriaan A. Voors,
Jorg Taubel,
Anke R. Hodes,
Mohamed Anwar,
Ravi Karra,
Yasushi Sakata,
Shiro Ishihara,
Roxy Senior,
Abhishek Khemka,
Narayana G. P Tags: Research Article Source Type: research
The Current Role of Clevidipine in the Management of Hypertension
AbstractAcute hypertension, which may damage blood vessels, causes irreversible organ damage to the vasculature, central nervous system, kidney, and heart. Clevidipine, the first third-generation calcium channel antagonist approved by the Food and Drug Administration (FDA) in the past 20 years, is an ultra-short-acting calcium channel blocker that inhibits L-type calcium channels with high clearance and low distribution, can be rapidly metabolized into the corresponding inactive acid, and is rapidly hydrolyzed into inactive metabolites by esterase in arterial blood. Clevidipine is the same as nicardipine in that the main p...
Source: American Journal of Cardiovascular Drugs - September 2, 2021 Category: Cardiology Source Type: research
IMPROvE-CED Trial: Intracoronary Autologous CD34+ Cell Therapy for Treatment of Coronary Endothelial Dysfunction in Patients With Angina and Non-Obstructive Coronary Arteries
Conclusion: A single IC autologous CD34+ cell infusion was safe and may potentially be an effective disease-modifying therapy for microvascular CED in humans. Clinical Trial Registration: NCT03471611.PMID:34923853 | DOI:10.1161/CIRCRESAHA.121.319644
Source: Circulation Research - December 20, 2021 Category: Cardiology Authors: Michel T Corban Takumi Toya Diana P Albers Faten Sebaali Bradley Lewis John P Pearce Bois Rajiv Gulati Abhiram Prasad Patricia J Best Malcolm Bell Charanjit Rihal Megha Prasad Ali Ahmad Lilach O Lerman Mary L Solseth Jeffrey L Winters Allan B Dietz Amir L Source Type: research
Classical prescription Dachuanxiong Formula delays nitroglycerin-induced pain response in migraine mice through reducing endothelin-1 level and regulating fatty acid biosynthesis
CONCLUSIONS: The present study revealed the anti-migraine effect of DCXF in migraine mice and provided insights into the mechanisms of DCXF-mediating anti-migraine treatment.PMID:35032586 | DOI:10.1016/j.jep.2022.114992
Source: Atherosclerosis - January 15, 2022 Category: Cardiology Authors: Chi Teng Vong Yulong Chen Zhejie Chen Caifang Gao Fengqing Yang Shengpeng Wang Yitao Wang Source Type: research
A comparative study of intravenous labetalol VS intravenous Nitroglycerin in the treatment of hypertensive crises
Indian Heart J. 2022 Jun 3:S0019-4832(22)00097-9. doi: 10.1016/j.ihj.2022.06.001. Online ahead of print.ABSTRACTHypertensive crises is still a major public health problem, causing end organ damage like myocardial infarction, stroke, and renal failure. Labetalol and nitroglycerine are among the two most commonly used medicine to control the blood pressure, but there is no head to head comparison between these two medicines. This was a prospective randomized non-blinded study which included 50 patients of hypertensive crises, out which 25 patients received intravenous labetalol and 25 patients received intravenous nitroglyce...
Source: Indian Heart J - June 6, 2022 Category: Cardiology Authors: M O H A M M A D A Z H A R U D D I N Malik R E H A N Ahmad M U J A H I D Beg R I Z W A N Ahmad Source Type: research
